发明申请
- 专利标题： DI(ARYLAMINO)ARYL COMPOUND
- 专利标题（中）： DI（ARYLAMINO）ARYL化合物
-
申请号： US13618732申请日： 2012-09-14
-
公开(公告)号： US20130096100A1公开(公告)日： 2013-04-18
- 发明人: Yutaka KONDOH , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
- 申请人： Yutaka KONDOH , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
- 申请人地址： JP Tokyo
- 专利权人： ASTELLAS PHARMA INC.
- 当前专利权人： ASTELLAS PHARMA INC.
- 当前专利权人地址： JP Tokyo
- 优先权： JP2007-178795 20070706
- 主分类号： A61K31/551
- IPC分类号： A61K31/551 ; A61K31/541 ; A61K31/53 ; A61K31/517 ; A61K31/5377
摘要：
The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
信息查询
